Transgenic animal as a model for fibrotic diseases

Details Transgenic animal as a model for fibrotic diseases Transgenic animal as a model for fibrotic diseases

2006-02-21

2010-10-05

Hill, Kevin K. (Department: 1633)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C435S004000, C435S007800, C435S021000, C436S063000

Reexamination Certificate

active

07807864

ABSTRACT:
Disclosed is a transgenic non-human animal with broad or cell type-specific ectopic expression of fra-2 that manifests itself in a fibrotic disease, methods for obtaining such animal and their use. Fra-2 transgenic animals, in particular mice, are useful as model systems for human fibrotic disease, e.g. lung scleroderma and pulmonary fibrosis. Cells obtained from the animal are useful for the analysis of fibrotic disease and for testing compounds useful in the therapy of fibrotic disease.

REFERENCES:
patent: 6492129 (2002-12-01), Grotendorst
Pope, J.E., Curr. Op. Rheumatol. 14: 704-710, 2002.
Chua et al, Am. J. Respir. Cell. Mol. Biol. 33: 9-13;2005.
Racay, Bratisl Lek Listy, 103: 121-126, 2002.
Sigmund, Arteroscler. Throm. Vasc. Biol. 20: 1425-1429, 2000.
Sandgren et al, Mol. Cell. Biol. 13(1): 320-330, 1993.
Jhappan et al, Cell 61: 1137-1146, 1990.
Kuroiwa et al, Nature Genetics 36(7):775-80, 2004.
Moreadith et al, J. Mol. Med. 75(3): 208-216, 1997.
Kappell et al, Current Opinion in Biotechnologv 3: 549-553, 1992.
Mullins et al, Hypertension 22: 630-633, 1993.
Houdebine, J. Biotech. 34: 269-287, 1994.
Cameron, Molec. Biotech. 7: 253-265, 1997.
Polejaeva et al, Theriogenology, 53(1):117-126, 2000.
Rulicke et al, Experimental Physiology 85: 589-601, 2000.
Mullins et al, Journal of Clinical Investigation 97(7): 1557-1560, 1996.
Pearson, Nature 415(6867):8-9, 2002.
Bishop, Reprod. Nutr. Dev. 36: 607-618, 1998.
Denning, Nat. Biotech. 19:559-562, 2001.
Humpherys et al, Science 293:95-97, 2001.
Wall et al, J Dairy Sci. 80:2213-2224, 1997.
Yanagimachi, Mol. Cell Endocrinol. 187:241-248, 2002.
Wall, Theriogenologv 45: 57-68, 1996.
Molven et al, Genomics 38(1):7-75, 1996.
Tokugawa et al, Mol. Immunol. 34(18):1263-1272, 1997.
Kaushansky et al, PNAS 86(4):1213-1217, 1989.
Chen et al, Cell Tissue Res. 329(1):169-178, 2007.
Ruther et al, Cell 53:847-856, 1988.
Jochum et al, Nature Medicine 6(8):980-984, 2000.
Nishina et al, PNAS 87:3619-3623, 1990.
Foletta et al, Oncogene 9:3305-3311, 1994.
Means et al, Gastroenterology 124:1020-1036, 2003.
Denton et al, J. Biol. Chem. 278(27):25109-25119, 2003.
Kolb et al, Am. J. Respir. Cell Mol. Biol. 27(2):141-150, 2002.
McHenry, Jane, Z.; Overexpression of fra-2 in transfenic mice perturbs normal eye development; Oncogene, vol. 17, No. 9, Sep. 3, 1998, pp. 1131-1140, XP002323126.
Schorpp, M., The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice; Nucleic Acids Research, Oxford University Press, Surrey, GB; vol. 24, No. 9, May 1, 1996; pp. 1787-1788; XP002121787.
Timblin, Cynthia; Ultrafine airborne particles cause increases in protooncogene expression and proliferation in alveolar epithelial cells; Toxicology and Applied Pharmacology, vol. 179, No. 2, Mar. 1, 2002; pp. 98-104, XP002313127.
Grigoriadis, A.E.; Osteoblasts are target cells for transformation in c-fox transgenic mice; Journal of Cell Biology, Rockfeller University Press, NY, NY, U.S., vol. 122, No. 3, Aug. 1993, pp. 685-701, XP002953461.

Affiliated with

Also associated with

Rating

Transgenic animal as a model for fibrotic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transgenic animal as a model for fibrotic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic animal as a model for fibrotic diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4233103